Biotechnology
Innovent and LG Chem Announce Strategic Collaboration for Tigulixostat, a Novel Non-Purine Xanthine Oxidase Inhibitor for the Treatment of Gout Disease
ROCKVILLE, Md. and SUZHOU, China, Dec. 15, 2022 /PRNewswire/ -- Innovent Biologics ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune, ophthalmology and other m...
Alternative Bio Launches with USD 15M Series Seed Financing Led by Eight Roads Ventures with F-Prime Capital and Sequoia China Seed Fund
SINGAPORE, Dec. 15, 2022 /PRNewswire/ -- Alternative Bio Inc. ("ABio"), a privately held biotechnology company developing novel therapeutics targeting a previously untapped class of post-translational modifying enzymes announced today its $15 million Series Seed financing co-led by Eight Roads Ve...
Everest Medicines Announces New mRNA Rabies Vaccine Program and Achievement of Preclinical Proof-of-Concept Milestone
Rabies program, as the first non-COVID19 vaccine developed with a specialized mRNA platform, highlights Everest's discovery capabilities Clinically validated mRNA platform is shown to generate differentiated products across a range of indications SHANGHAI, Dec. 15, 2022 /PRNewswire/ -- Everest M...
Novavax Announces Proposed $125 Million Public Offering of Common Stock
GAITHERSBURG, Md., Dec. 15, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced a proposed underwritten public offering to sell up to $125 million of its c...
Sirnaomics Announces Positive Interim Data from Phase IIb Clinical Trial of STP705 in Adults with Cutaneous Squamous Cell Carcinoma In Situ
Dose escalation cohort study is evaluating the safety, tolerability and efficacy of various doses of STP705 administered as intralesional injection in subjects with isSCC GERMANTOWN, Md. and SUZHOU BIOBAY, China, Dec. 14, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock...
Actinogen announces first patient treated in depression and cognitive impairment Phase 2 clinical trial
Approximately 5% of Americans suffer from Major Depressive Disorder (MDD),[1] which is commonly associated with "foggy thinking" but a new clinical trial raises hope that once-a-day oral drug Xanamem® may assist where treatment by anti-depressant medication alone is inadequate SYDNEY, Dec. 14, 2...
Circulating Tumor Cell detection by Menarini Group's CELLSEARCH® System leading to genomic profiling of myeloma cells shows potential for non-invasive management of Multiple Myeloma patients at early stages of disease
Researchers at Dana-Farber Cancer Institute showed that enumeration of circulating tumor cells (CTCs)with Menarini Silicon Biosystems' CELLSEARCH® System and the CELLSERCH® Circulating Multiple Myeloma Cell (CMMC) Test* can be used to monitor and manage patients with Multiple Myeloma (MM) even at...
Superior Results Of The Comparative Study Of The Company's Recombinant Two-Component COVID-19 Vaccine ReCOV As Compared To International Mainstream mRNA Vaccine
TAIZHOU, China, Dec. 14, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that positive results were achieved for its sequential booster vaccination Phase II study of the recombinant twocomponent COVID-19 ...
Sirnaomics Executive Director Dr. Xiaochang Dai to Deliver Keynote Speech at BIOHK2022
GERMANTOWN, Md. and HONG KONG, Dec. 14, 2022 /PRNewswire/ -- Sirnaomics Ltd. ( the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in the discovery and development of advanced therapeutics centered around the messenger RNA ("mRNA"), announced today that its Ex...
Sirnaomics Executive Director Dr. Xiaochang Dai to Deliver Keynote Speech at BIOHK2022
GERMANTOWN, Md. and HONG KONG, Dec. 13, 2022 /PRNewswire/ -- Sirnaomics Ltd. ( the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in the discovery and development of advanced therapeutics centered around the messenger RNA ("mRNA"), announced today that its Ex...
Treadwell Therapeutics Announces A Presentation at the 2022 ASH Annual Meeting Featuring a Clinical Trial Update on CFI-400945, an oral PLK4 inhibitor
NEW YORK, Dec. 13, 2022 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage biotechnology company developing novel, small molecule therapeutics for highly aggressive cancers, today announced a presentation for the Company's CFI-400945 program, a first in class inhibitor of Polo-like Kinase ...
VeriSIM Life Earns Frost & Sullivan Competitive Strategy Leadership Award for Best Practices in AI-enabled Preclinical Development Industry
VeriSIM Life eliminates waste and inaccuracy, accelerates preclinical development, and lowers costs and risks when converting drug candidates to clinical trials, and brings life-saving drugs to market faster. SAN ANTONIO, Dec. 13, 2022 /PRNewswire/ -- Frost & Sullivan recently assessed the artif...
Biosion Announces Research Collaboration with ImmunoGen to Create Novel Antibody-Drug Conjugates
Collaboration to explore potential of creating next-generation antibody-drug conjugateswith Biosion's SynTracer® internalization platform and ImmunoGen's proprietary linker-payload technology NEWARK, Del., Dec. 13, 2022 /PRNewswire/ -- Biosion USA, Inc. (Biosion), a global R&D biotechnology comp...
Live from ASH 2022 | Ascentage Pharma Presents Latest Data of APG-2575, Including Encouraging Results of the Combination with BTKi in Patients with R/R CLL/SLL
SUZHOU, China and ROCKVILLE, Md. , Dec. 13, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it has released preliminary results from a ...
RemeGen's RC118 for Injection Targeting Claudin 18.2 in Patients with Gastric and Pancreatic Cancers Granted Two Orphan Drug Designations by U.S. FDA
YANTAI, China, Dec. 13, 2022 /PRNewswire/ -- RemeGen Co., Ltd.
CSL Announces Next CEO & Managing Director
Dr Paul McKenzie appointed Chief Executive Officer and Managing Director of CSL from6 March 2023 MELBOURNE, Australia, Dec. 13, 2022 /PRNewswire/ -- The Board of Directors of CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that it has appointed DrPaul McKenzie as Chief Executive Officer (CEO)...
Ascletis Announces Positive Phase I Clinical Results of Oral RdRp Inhibitor ASC10 for COVID-19
--The exposure of active drug ASC10-A after twice daily dosing 800 mg double prodrug ASC10 in Chinese subjects was 94% of that after twice daily dosing 800 mg single prodrug molnupiravir in Japanese subjects --Based on Ascletis' Phase I results of ASC10 and molnupiravir's clinical efficacy data ...
CARsgen Presents Data from China Pivotal Phase II Trial of BCMA CAR T Zevor-cel (CT053) at 2022 ASH Annual Meeting
SHANGHAI, Dec. 12, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces thatat the 2022 American Society of Hematology (the "ASH") Annual Mee...
PharmAbcine Announces Collaboration Agreement with MSD to Evaluate Anti-VISTA Antibody PMC-309 in Combination with KEYTRUDA® (pembrolizumab)
DAEJEON, South Korea, Dec. 12, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that the Company has entered into a clinical collaboration agreement with MSD (Merck & Co...
Asieris'Bladder Cancer Diagnostic Drug Hexvix® Completed Dosing of First Patient in Real-World Clinical Study
SHANGHAI, Dec. 12, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that Hexvix®, a drug used for bladder c...
Week's Top Stories
Most Reposted
Protiviti Transforms Cyber Risk Consulting with CYFIRMA's Advanced Intelligence-Led Cybersecurity
[Picked up by 324 media titles]
2024-04-15 09:00Sephora appoints Xia Ding as Managing Director of Sephora Greater China
[Picked up by 309 media titles]
2024-04-15 17:33With unique features, Hainan TV opened "The World's Specialty" pavilion at the Expo!
[Picked up by 281 media titles]
2024-04-18 21:26Animated Life in Yunnan
[Picked up by 278 media titles]
2024-04-18 14:00China's Yiwu Establishes Welcoming Committee to Attract International Buyers
[Picked up by 276 media titles]
2024-04-19 13:25